ICP DAS-BMP, a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will The product will be exhibited for the first time at 2023 (2023 Seoul Medical Equipment Hospital Equipment and Healthcare Exhibition in Korea). Exhibit highlights include TPU particles containing radioactive additives such as 50% tungsten (W50) and 40% barium sulfate (B40), respectively. The medical equipment and hospital equipment exhibition will be held in Seoul from March 23rd to 26th.
ICP DAS will exhibit three series of high-stability medical TPU particles, namely Alithane™ (ALP series), Durathane™ (ALC series) and Arothane™ (ARP series). All TPU particles have passed USP Class VI testing and/or ISO 10993 biocompatibility testing.
In order to distinguish it from the composite process, ICP DAS Biomedical has developed a unique one-step polymerization process to produce TPU particles containing masterbatches and radiopaque fillers, thereby enhancing the performance characteristics of the material for various medical applications, including medical catheters, Cancer treatment devices and guide wire coatings.
The company also conducts a thorough quality inspection of each batch of products produced to ensure batch-to-batch consistency of medical TPU particles and meet customer requirements, namely mechanical and physical properties and processing performance.
Expert teams, rigorous testing, superior performance, and shorter lead times all earn the trust and confidence of manufacturers worldwide. The company expects its TPU sales in China, India, Europe and the United States to increase this year, and the company has the strength to stand out in this field globally.
Introduction to ICP DAS Biomedical Polymers
In response to the growing demand for TPU in the global medical application field, in 2018, ICP DAS Technology (ICP DAS) established a new business unit, ICP DAS Biomedical Polymers, responsible for the development and production of medical-grade TPU. The company's TPU has received ISO 13485 production certification to ensure product safety and quality.
ICP DAS Biomedical Polymers has its own laboratories for polymerization processing, physical and chemical analysis, mechanical testing and cytotoxicity testing. In addition, the TPU produced by the company has passed USP Class VI and ISO 10993 certification. Among them, ISO 10993-4 is blood compatibility test, ISO 10993-5 is cytotoxicity test, ISO 10993-10 is irritation and skin allergy test, ISO 10993-11 is the system toxicity test, and ISO 10993-23 is the irritation test. The company's product series also meet the requirements of REACH and RoHS.
微信扫一扫打赏
